Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma
Purpose. It has been reported that Th2 cytokines downregulate antitumor immunity, while activation of type T cells promotes antitumor immunity. The aim of this paper was to evaluate host immunity in liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) receiving sorafenib thera...
Saved in:
Main Authors: | Hidenari Nagai, Takanori Mukozu, Daigo Matsui, Takenori Kanekawa, Masahiro Kanayama, Noritaka Wakui, Kouichi Momiyama, Mie Shinohara, Kazunari Iida, Koji Ishii, Yoshinori Igarashi, Yasukiyo Sumino |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | Clinical and Developmental Immunology |
Online Access: | http://dx.doi.org/10.1155/2012/607851 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PHARMACOECONOMICAL RESEARCH OF THE USE OF SORAFENIB IN MALIGNANT TUMORS
by: M. Y. Frolov, et al.
Published: (2016-09-01) -
Sorafenib-Induced Liver Failure: A Case Report and Review of the Literature
by: Anneleen Van Hootegem, et al.
Published: (2011-01-01) -
Thermally Driven Atmospheric Escape: Transition from Diffusion-limited to Drag-off Escape
by: Jack C. Evans, et al.
Published: (2025-01-01) -
Use of Adjuvant Sorafenib in Liver Transplant Recipients with High-Risk Hepatocellular Carcinoma
by: Kirti Shetty, et al.
Published: (2014-01-01) -
Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment
by: Jiarui Lv, et al.
Published: (2025-01-01)